Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Carcinoma, Hepatocellular 3Waldenstrom Macroglobulinemia 2Sezary Syndrome 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Mycosis Fungoides 2Melanoma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Prolymphocytic 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Breast Neoplasms 2Uveal Melanoma 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocythemia, Essential 1

Interventions

Doxorubicin 9Specimen Handling 7Sorafenib 7Erlotinib Hydrochloride 7Oxaliplatin 6Magnetic Resonance Spectroscopy 6Leucovorin 6Fluorouracil 5Thalidomide 4Radiofrequency Ablation 4Bevacizumab 4tremelimumab 3cediranib 3cabozantinib 3Trastuzumab 3Pharmacogenomic Testing 3Nivolumab 3Neoadjuvant Therapy 3Melphalan 3MK 2206 3Irinotecan 3Fluorodeoxyglucose F18 3Dasatinib 3Cisplatin 3Chemotherapy, Adjuvant 3Bortezomib 3Biopsy 3AZD 6244 3trametinib 2sargramostim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Carcinoma, Hepatocellular × Pharmacogenomic Testing × Clear all
NCT01015833 2022-08-04

Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

National Cancer Institute (NCI)

Phase 3 Completed
356 enrolled 13 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT01859182 2014-09-09

Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 2 Withdrawn
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular

NCT01324076 2011-05-13

Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 3 Unknown
412 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡